GlassScriptPhysician profile
Peter Dennis Corda
NPI 1861477192
$4,137.45
in general payments reported to CMS, 2019-2025
28 companies · $409 in 2025
The $409 reported for 2025 was more than what 89% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,034 · 2020: $196 · 2021: $629 · 2022: $327 · 2023: $219 · 2024: $323 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,807.28 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $593.77 | 2019-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $412.21 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $242.02 | 2021-2025 | General - Pain Management, Patient Trial Kit |
| Medtronic USA, INC. | $145.59 | 2019 | |
| Si-Bone, INC. | $128.69 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.53 | 2019-2024 | Relistor |
| Biodelivery Sciences International, INC. | $110.70 | 2019-2021 | |
| Protega Pharmaceutials INC | $60.06 | 2022-2024 | Roxybond |
| Zyla Life Sciences, INC. | $59.75 | 2019-2020 | |
| Horizon Therapeutics Plc | $55.63 | 2019 | |
| Mdd US Operations, LLC | $51.74 | 2019-2020 | |
| Globus Medical, INC. | $38.60 | 2025 | Senza |
| Fidia Pharma USA INC. | $36.46 | 2023 | Hymovis |
| Teva Pharmaceuticals USA, INC. | $34.01 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $29.36 | 2019 | |
| Saluda Medical Americas, INC. | $29.32 | 2025 | Evoke |
| Pfizer INC. | $26.30 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.34 | 2025 | |
| Stratus Medical, LLC | $15.67 | 2023 | Nimbus |
| Azurity Pharmaceuticals, INC. | $14.84 | 2025 | Horizant |
| Medtronic, INC. | $14.83 | 2022 | |
| Pernix Therapeutics Holdings, INC. | $14.81 | 2019 | |
| Ibsa Pharma INC. | $14.78 | 2023 | Tirosint, Licart |
| Arbor Pharmaceuticals, INC. | $14.33 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.16 | 2021 | |
| Painteq LLC | $13.95 | 2024 | Painteq |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Corda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.